资讯

MyChesCo on MSN2 小时
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer
Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...
GlobalData on MSN6 天
AstraZeneca, Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...
Fierce Pharma7 天
AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...
PharmiWeb7 天
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety ...
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed ...
Seeking Alpha7 天
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSNKY) announced Wednesday that Enhertu, their jointly developed antibody-drug conjugate, reached the main goal in a Phase 3 trial in certain ...
The Pharma Letter7 天
AstraZeneca and Daiichi push Enhertu into earlier breast cancer use
UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...
pharmaphorum7 天
New data could move Enhertu into early breast cancer
AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...